Delivery of Care for Pediatric Patients Receiving Blinatumomab: A Children's Oncology Group Study.
Janice S Withycombe, Holly R Kubaney, Maki Okada and 6 others
PMID 38016041WHAT IT FOUND
Pediatric blinatumomab care varied widely.
Most patients went home during the first week, often without home health, and many used 72- or 96-hour bags. Pump and line problems were common, especially outpatient.
Key findings
01Most patients were discharged home during the first week of the 28-day cycle, and 79% of institutions using multiple bag sizes reported 72- or 96-hour combinations.
02Only 9% of institutions reported no outpatient pump or equipment issues; the most common outpatient issue was line break or leak at 57%.
03During the first 72 inpatient hours, every 4 hours was the most common interval for vital signs and neurological checks, and 51% reported a lower nurse-to-patient ratio than usual.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
It reports institutional practices, not patient outcomes, so it cannot show that any practice improves safety, toxicity, or family burden. One respondent per institution reported practices for the whole institution, and some answers may have relied on incomplete information from other units. Non-responding institutions were not described, and institutions with less blinatumomab experience may have been less likely to respond. The survey did not capture families' experience of home infusion. Data were collected during the COVID-19 pandemic, which may have affected practices or responses.
Declared interests
The paper is listed as receiving NIH extramural research support, and the institutions affiliated with the PI received funding through the National Clinical Trials Network. No other authors declared conflicts of interest.
The easy way to misread this
Do not read this as proof that home blinatumomab is safe or that any specific practice reduces harm. It describes what institutions reported doing and what problems they noticed, not patient outcomes or a controlled comparison.